GOSS Stock Forecast & Price Target

Gossamer Bio is attractive because seralutinib has a credible path to approval in pulmonary arterial hypertension, supported by PROSERA and TORREY, with the FDA framing the statistical-significance question as a review issue rather than a filing barrier. The company’s July and mid-June pre-NDA interactions suggest NDA acceptance is achievable, while an expert call described a “medium-high” approval chance, a likely broad Group 1 label, and early, additive use alongside sotatercept rather than as a niche therapy. Fundamentally, the stock’s upside rests on a large unmet need, a differentiated inhaled anti-proliferative/anti-inflammatory/anti-fibrotic mechanism, and the possibility of capturing roughly 10% of treated US PAH patients if launch execution is successful.

Gossamer Bio is facing a deeply challenged investment case because seralutinib, the main value driver, failed to hit its prespecified statistical threshold in PROSERA, leaving FDA free to conclude that the Phase 3 data plus TORREY and other evidence still do not show substantial effectiveness. Safety also weakens the story, with discontinuations due to adverse events about three times higher than placebo (15.0% versus 5.8%) and adverse events of special interest more frequent (20.5% versus 6.3%), while a negative regulatory decision could force a Complete Response Letter, extra study, or narrower label. Beyond regulation, the company now bears full development and commercialization responsibility after Chiesi’s exit, faces dilution risk if more capital is needed, and must compete in a crowded PAH market where launch execution, payer access, and differentiation remain uncertain.